Press Enter to search · Esc to close
The shots that started as diabetes drugs and exploded as weight-loss icons are turning out to do a lot more than mute hunger. New research traces their fingerprints across the hindbrain, the kidney's salt switches, and the hormone that tells you it's lunchtime.
Three 2025 studies suggest the new generation of metabolic drugs reaches further than the scale — into addiction risk, liver fat, and the realities of treating people over 65. The evidence is promising, and still maturing.
A new BMJ study using UK primary care data compared GLP-1 users head-to-head with other diabetes drugs — and the suicide-risk signal regulators have been chasing didn't show up.
New single-cell research suggests the fat around your middle isn't just storing energy — it may be quietly broadcasting aging signals to the rest of your body.
A wave of 2025 reviews and trial analyses sketches what comes after tirzepatide — broader populations, bigger weight-loss numbers, and tentative steps into autoimmune diabetes.
Three new reviews argue we've been measuring the wrong thing. The real target isn't weight — it's the adipose tissue quietly running your metabolism.
A major new synthesis argues obesity is not just a metabolic condition but a fundamentally altered immunological state — reshaping how we think about GLP-1s, weight loss, and the body's defenses.
New 2025 data hints that GLP-1 drugs may quiet inflammation in the liver and skin — but a sober pharmacology review reminds us the price tag, and the science, are still catching up.
Two fresh analyses push the GLP-1 conversation past nausea, flagging ear-nose-throat signals and a higher risk of failed bowel prep. Here's what tired parents juggling a new prescription actually need to know.
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.